Contact
Please use this form to send email to PR contact of this press release:
Targovax announces completion of safety lead-in and preliminary immune activation data in ONCOS-102 trial in mesothelioma
TO:
Please use this form to send email to PR contact of this press release:
Targovax announces completion of safety lead-in and preliminary immune activation data in ONCOS-102 trial in mesothelioma
TO: